AR017973A1 - PHARMACEUTICAL ISOTONIC FORMULATION, USE OF SUCH FORMULATION IN THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE THERAPY OF AN AUTOIMMUNE DISEASE, AND METHOD FOR IMPROVING THE STORAGE OF AN ANTIBODY - Google Patents
PHARMACEUTICAL ISOTONIC FORMULATION, USE OF SUCH FORMULATION IN THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE THERAPY OF AN AUTOIMMUNE DISEASE, AND METHOD FOR IMPROVING THE STORAGE OF AN ANTIBODYInfo
- Publication number
- AR017973A1 AR017973A1 ARP990100239A ARP990100239A AR017973A1 AR 017973 A1 AR017973 A1 AR 017973A1 AR P990100239 A ARP990100239 A AR P990100239A AR P990100239 A ARP990100239 A AR P990100239A AR 017973 A1 AR017973 A1 AR 017973A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- antibody
- storage
- formulations
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Formulacion farmacéutica isotonica que comprende un anticuerpo de IgG y un buffer, donde el anticuerpo está presente en, de 0,5 mg/ml a 10 mg/ml, elbuffer es un buffer de citrato presente en, de 5 mmol/l a 20 mmol/l y el pH de la formulacion es de 5,3 a 7,2. Las proteínas purificadas, particularmenteaquellas producidas usando tecnología de ADN recombinante, están ahora bien establecidas como agentes farmacéuticos. Dichas proteínas presentansin embargo, un rango de problemas asociados con su formulacion estable. Muchas preparaciones de proteínas son particularmente inestables en solucionesdiluidas y deben formularse de tal manera de prevenir niveles significativos de desnaturalizacion, aglomeracion o degradacion. Estos problemas sonparticularmente graves en la formulacion de proteínas grandes, tales como inmunoglobulinas. Las inmunoglobulinas o anticuerpos son propensos a formaragregados y particulados en solucion y desde hace bastante tiempo, esto ha llevado a problemas especiales paragenerar formulaciones adecuadaspara el almacenamiento y la administracion de anticuerpos terapéuticos. Las formulaciones de anticuerpos existentes requieren con frecuencia filtrarseantes de la inyeccion para extraer agregados o material particuladoque sea inconveniente y tienda a reducir la precision de la dosis inyectada.La presente formulacion de anticuerpos es más simple que aquella actualmente conocida, es adecuada para la administracion y mejora las propiedadesde almacenamiento. Las formulaciones de anticuerpos, requieren tanto el uso de un estabilizador como de un buffer. Sin embargo, los anticuerpos en laspresentes formulaciones se estabilizan solamente por el buffer de citrato en una solucion salina en un pH fisiologicamente preferible. Uso de dichaformulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune, y método para mejorar el almacenamiento de un anticuerpo.Isotonic pharmaceutical formulation comprising an IgG antibody and a buffer, where the antibody is present in, from 0.5 mg / ml to 10 mg / ml, elbuffer is a citrate buffer present in, from 5 mmol / la 20 mmol / The pH of the formulation is 5.3 to 7.2. Purified proteins, particularly those produced using recombinant DNA technology, are now well established as pharmaceutical agents. Such proteins, however, have a range of problems associated with their stable formulation. Many protein preparations are particularly unstable in dilute solutions and should be formulated in such a way to prevent significant levels of denaturation, agglomeration or degradation. These problems are particularly serious in the formulation of large proteins, such as immunoglobulins. Immunoglobulins or antibodies are prone to spreading and particulate in solution and for quite some time, this has led to special problems to generate appropriate formulations for the storage and administration of therapeutic antibodies. Existing antibody formulations often require filtering before injection to extract aggregates or particulate matter that is inconvenient and tends to reduce the accuracy of the injected dose. The present antibody formulation is simpler than that currently known, is suitable for administration and Improves storage properties. Antibody formulations require both the use of a stabilizer and a buffer. However, the antibodies in the present formulations are stabilized only by the citrate buffer in a saline solution at a physiologically preferable pH. Use of said formulation in the preparation of a medicament for use in the therapy of an autoimmune disease, and method for improving the storage of an antibody.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9800170A SE9800170D0 (en) | 1998-01-22 | 1998-01-22 | formulation |
SE9800766A SE9800766D0 (en) | 1998-03-09 | 1998-03-09 | formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
AR017973A1 true AR017973A1 (en) | 2001-10-24 |
Family
ID=26663196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990100239A AR017973A1 (en) | 1998-01-22 | 1999-01-21 | PHARMACEUTICAL ISOTONIC FORMULATION, USE OF SUCH FORMULATION IN THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE THERAPY OF AN AUTOIMMUNE DISEASE, AND METHOD FOR IMPROVING THE STORAGE OF AN ANTIBODY |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR017973A1 (en) |
AU (1) | AU2444899A (en) |
WO (1) | WO1999037329A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
US20030124119A1 (en) * | 1999-12-28 | 2003-07-03 | Tadao Yamazaki | Stable antibody compositions and injection preparations |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
TW200510532A (en) | 2003-07-15 | 2005-03-16 | Chugai Pharmaceutical Co Ltd | IgM production by transformed cell and method of quantifying the same |
EP1698640B2 (en) | 2003-10-01 | 2019-06-19 | Kyowa Hakko Kirin Co., Ltd. | Method of stabilizing antibody and stabilized solution-type antibody preparation |
JP4762717B2 (en) | 2003-10-09 | 2011-08-31 | 中外製薬株式会社 | IgM high concentration stabilization solution |
US7803914B2 (en) | 2003-10-09 | 2010-09-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for stabilizing protein solutions |
EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
ES2376556T3 (en) * | 2004-03-24 | 2012-03-14 | Abbott Biotherapeutics Corp. | USE OF ANTI-ALFA5BETA1 ANTIBODIES TO INHIBIT THE PROLIFERATION OF CANCEROSE CELLS. |
TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
WO2007124299A2 (en) * | 2006-04-21 | 2007-11-01 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
WO2013103783A1 (en) * | 2012-01-04 | 2013-07-11 | Sanofi Us | Murine il-13 antibodies |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
KR102238677B1 (en) | 2012-09-07 | 2021-04-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | Stable aqueous formulations of adalimumab |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0417191B1 (en) * | 1988-05-27 | 1993-03-10 | Centocor, Inc. | Formulation for antibody reagents |
CA2049342A1 (en) * | 1989-03-27 | 1990-09-28 | Sally Bolmer | Formulations for stabilizing of igm antibodies |
JPH0565233A (en) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | Monoclonal antibody-containing lyophilized preparation |
JP4157160B2 (en) * | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | Methods for the preparation of modified antibody variable regions |
GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
-
1999
- 1999-01-15 WO PCT/SE1999/000049 patent/WO1999037329A1/en active Application Filing
- 1999-01-15 AU AU24448/99A patent/AU2444899A/en not_active Abandoned
- 1999-01-21 AR ARP990100239A patent/AR017973A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1999037329A1 (en) | 1999-07-29 |
AU2444899A (en) | 1999-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR017973A1 (en) | PHARMACEUTICAL ISOTONIC FORMULATION, USE OF SUCH FORMULATION IN THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE THERAPY OF AN AUTOIMMUNE DISEASE, AND METHOD FOR IMPROVING THE STORAGE OF AN ANTIBODY | |
KR950014915B1 (en) | Asialoglycoprotein-conjugated compounds | |
CA1329543C (en) | Human growth hormone formulation | |
KR101363237B1 (en) | Stable formulations containing enhancing proportions of gamma- and alpha-interferons | |
Gresser et al. | Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. | |
DE69434418D1 (en) | Oral dosage form | |
JPH03504967A (en) | Chimeric peptides for neuropeptide transport across the blood-brain barrier | |
JPH03502197A (en) | Novel anti-inflammatory agent | |
BRPI0616300A2 (en) | hfsh aqueous formulation | |
AR052198A1 (en) | ANTI-BETA ANTIBODY FORMULATIONS | |
PT88626B (en) | Process for the preparation of a polyphenol-based growth factor of milk | |
JPH07506113A (en) | Pharmaceutical formulations for inhibiting tumors associated with prostate cancer, gastric cancer and breast cancer | |
Tsutsumi et al. | PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency | |
CA2376894C (en) | Pharmaceutical composition comprising a protein and an ectoine | |
KR900015749A (en) | Interleukin-1 formulation | |
ES2908141T3 (en) | Formulations and doses of cannabinoids | |
DK1173476T3 (en) | Functional soybean proteins | |
JPH06247872A (en) | Tcf preparation having high concentration | |
JPH0640938A (en) | Hgf-containing pharmaceutical preparation | |
ES2329204T3 (en) | ANTIVIRAL COMPOSITION THAT INCLUDES INTERFERED IN THE FORM OF NASAL DROPS. | |
JP3030386B2 (en) | Anticancer agent | |
JPH0441421A (en) | Pulmonary absorbable composition | |
JPS6360940A (en) | Preventive or remedy for cataract | |
ES2226326T3 (en) | HUMAN GROWTH HORMONE TO STIMULATE HEMATOPOYESIS AND RECONSTITUTION OF THE IMMUNE SYSTEM AFTER HEMATOPOYETIC MOTHER CELL TRANSPLANTATION IN HUMAN BEINGS. | |
JP2655667B2 (en) | Stable aqueous composition containing antibody |